Association of rapidly progressive moyamoya syndrome with bevacizumab treatment for glioblastoma in a child with neurofibromatosis type 1.
Neurofibromatosis type 1 is a common multisystemic disorder that can result in tumors of the central and peripheral nervous system. Individuals with neurofibromatosis type 1 are also at increased risk to develop moyamoya syndrome, which is a cerebrovascular condition that predisposes affected individuals to develop strokes as a result of progressive narrowing of the intracranial internal carotid arteries and failure of adequate blood supply through collateral vessels. We report a case of a young boy with neurofibromatosis type 1 with glioblastoma who developed rapidly progressive moyamoya vasculopathy after treatment with the angiogenesis inhibitor bevacizumab.
Ullrich
Nicole J
NJ
Department of Neurology, Children's Hospital Boston, Boston, MA 02446, USA. nicole.ullrich@childrens.harvard.edu
Zimmerman
Maryann
M
Smith
Edward
E
Irons
Mira
M
Marcus
Karen
K
Kieran
Mark W
MW
D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002648:Child; D018450:Disease Progression; D005909:Glioblastoma / Q000150:complications / Q000628:therapy*; D006801:Humans; D008297:Male; D009072:Moyamoya Disease / Q000209:etiology*; D009456:Neurofibromatosis 1 / Q000150:complications / Q000628:therapy*
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab